ReachMD
CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Mindenképp látogasd meg a podcast oldalát, és támogasd a készítőjét: reachmd.com
Hol hallgathatod?
Podcastok az alkalmazásban Replaio Radio HamarosanA podcastok hamarosan megérkeznek az alkalmazásba. Telepítsd most, és láss elsőként egy teljesen új megközelítést a podcastokhoz
Telepítsd ingyen
Android közel 10 M letöltés · 4,8-as értékelés
iOS hamarosan
Epizódok
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond 31.03.2025 5:15
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
From Guidelines to Practice: First-Line Treatment Choices in mCRC 31.03.2025 5:30
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection 31.03.2025 5:45
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Key Patient Counseling Issues Surrounding FNAIT and Its Risk in Subsequent Pregnancies 31.01.2025 5:00
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Nipocalimab: An FcRn Inhibitor and Its Role in Treating HDFN 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Neonatal FcRn Inhibition: A New Pathway for Addressing the Alloimmune Disorders of Pregnancy 31.01.2025 3:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Screening for FNAIT: Anticipating HPA-1a Incompatibility 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Managing the “Next Pregnancy” in Patients With an FNAIT-Affected First Child 31.01.2025 5:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Current Management Strategies for FNAIT 31.01.2025 5:00
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Current Diagnostic Signs, Symptoms, and Lab Tests for FNAIT 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Classification/Suspecting a Diagnosis of FNAIT/NAIT 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): The Platelet Equivalent of Rh Disease 31.01.2025 5:15
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
The Alloimmune Disorders of Pregnancy 31.01.2025 3:30
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Key Patient Counseling Issues Surrounding FNAIT and Its Risk in Subsequent Pregnancies 31.01.2025 5:00
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Nipocalimab: An FcRn Inhibitor and Its Role in Treating HDFN 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Neonatal FcRn Inhibition: A New Pathway for Addressing the Alloimmune Disorders of Pregnancy 31.01.2025 3:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Screening for FNAIT: Anticipating HPA-1a Incompatibility 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Managing the “Next Pregnancy” in Patients With an FNAIT-Affected First Child 31.01.2025 5:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Current Management Strategies for FNAIT 31.01.2025 5:00
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Current Diagnostic Signs, Symptoms, and Lab Tests for FNAIT 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Classification/Suspecting a Diagnosis of FNAIT/NAIT 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): The Platelet Equivalent of Rh Disease 31.01.2025 5:15
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
The Alloimmune Disorders of Pregnancy 31.01.2025 3:30
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL 14.01.2025 20:15
Host: Jorge E. Cortes, MD Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require further treatment with second- and third-line therapy. The development of newer drugs with unique mechanisms that can overcome these resistance phenotypes offers new treatment strategies that...
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL 14.01.2025 20:15
Host: Jorge E. Cortes, MD Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require further treatment with second- and third-line therapy. The development of newer drugs with unique mechanisms that can overcome these resistance phenotypes offers new treatment strategies that...
Hasonló podcastok
Hallgasd a(z) CME/CE podcastot a Replaióban
Rádió és podcastok egy alkalmazásban - ingyen és regisztráció nélkül. Telepítsd még ma, és ne maradj le a premierről
A Replaio nem podcastkiadó; a műsorok nevei, borítóképei és hanganyagai a szerzőiket illetik, és nyilvános RSS-csatornákon keresztül terjednek.
